 SAN JOSE, Calif., Feb. 08, 2021 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that on January 25, 2021, the National Medical Products Administration the NMPA, Chinas medical product regulatory authority, has approved for AnPac Bio to start the registration testing of its Class III lung cancer auxiliary diagnosis medical device at a designated medical device testing laboratory, which is a significant step towards obtaining a Class III medical device registration certificate by AnPac Bio. AnPac Bio began its medical device registration application process in December 2018, by filing an application for medical device classification with the NMPA. Since then, AnPac Bio has obtained the determination of the product classification recommended as Class III from the NMPA, and carried out medical device optimization, internal medical device testing and external third party testing and validation, and obtained the certificate of designated inspection capability from the designated medical device registration testing laboratory. Once the medical device passes the product registration testing, the next major step will be a clinical trial. AnPac Bio plans to conduct the clinical trial in at least two qualified clinical trial medical institutions, each of which is expected to enroll at least 300 subjects covering the control group and the confirmed lung cancer group. 